Emergent in $75m expansion into viral vectors and gene therapy

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Indysystem)
(Image: Getty/Indysystem)

Related tags: Emergent biosolutions, Gene therapy, Viral vectors, COVID-19, Coronavirus

The company will buildout its Massachusetts facility to provide CDMO services for viral vector and gene therapies.

Emergent BioSolutions, a contract development and manufacturing organization (CDMO) currently focused on biologics, plans to widen the range of its offerings by adding viral vector and gene therapy services.

According to the company, this will involve a ‘molecule-to-market’ service, once it has completed the $75m (€67m) investment into its Canton, Massachusetts site.

The capital will be put towards buying a property adjacent to its existing live viral drug substance facility, with the expanded area being a ‘multi-suite operation’ holding capacity up to the 1,000L scale.

Once the work is completed, the CDMO expects to be able to offer advanced therapy drug substance manufacturing services by the beginning of 2023.

Complementing the Canton site are Emergent’s additional locations in the US, as the company offers development services out of its Gaithersburg location and drug product manufacturing from Rockville, with the latter site also being expanded and with a completion date set for the end of 2021.

Contracted against COVID-19

Alongside a growing manufacturing footprint, the company has found its services in demand during the novel coronavirus outbreak.

The US government provided the company with a $628m contract​ to provide CDMO services for COVID-19 programs, with Emergent set to use part of this funding towards expanding drug product fill/finish capacity.

Prior to this, Emergent had already sealed a manufacturing partnership with Johnson & Johnson​ to develop its lead COVID-19 vaccine candidate – as the latter company worked towards securing a supply of one billion doses for its potential vaccine.

Related news

Show more

Related products

show more

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more